The necessity to verify the accuracy, sensitivity, and specificity of platelet GSK-3β activation as a predictive biomarker for cognitive impairment, as well as its potential application in a broader range of diseases, needs to be verifying in more large-scale, longitudinal studies. This evidence concerns the gene GSK3B and Cognitive impairment.